These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34732695)

  • 1. Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial.
    Hjorth OR; Frick A; Gingnell M; Hoppe JM; Faria V; Hultberg S; Alaie I; Månsson KNT; Rosén J; Reis M; Wahlstedt K; Jonasson M; Lubberink M; Antoni G; Fredrikson M; Furmark T
    Transl Psychiatry; 2021 Nov; 11(1):559. PubMed ID: 34732695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy.
    Hjorth O; Frick A; Gingnell M; Engman J; Björkstrand J; Faria V; Alaie I; Carlbring P; Andersson G; Jonasson M; Lubberink M; Antoni G; Reis M; Wahlstedt K; Fredrikson M; Furmark T
    Transl Psychiatry; 2022 Oct; 12(1):436. PubMed ID: 36202797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial.
    Faria V; Gingnell M; Hoppe JM; Hjorth O; Alaie I; Frick A; Hultberg S; Wahlstedt K; Engman J; Månsson KNT; Carlbring P; Andersson G; Reis M; Larsson EM; Fredrikson M; Furmark T
    EBioMedicine; 2017 Oct; 24():179-188. PubMed ID: 29033138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and co-expression of serotonin and dopamine transporters in social anxiety disorder: a multitracer positron emission tomography study.
    Hjorth OR; Frick A; Gingnell M; Hoppe JM; Faria V; Hultberg S; Alaie I; Månsson KNT; Wahlstedt K; Jonasson M; Lubberink M; Antoni G; Fredrikson M; Furmark T
    Mol Psychiatry; 2021 Aug; 26(8):3970-3979. PubMed ID: 31822819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial.
    Zoons E; Tijssen MAJ; Dreissen YEM; Smit M; Booij J
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32521736
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduced serotonin synthesis and regional cerebral blood flow after anxiolytic treatment of social anxiety disorder.
    Frick A; Åhs F; Appel L; Jonasson M; Wahlstedt K; Bani M; Merlo Pich E; Bettica P; Långström B; Lubberink M; Fredrikson M; Furmark T
    Eur Neuropsychopharmacol; 2016 Nov; 26(11):1775-1783. PubMed ID: 27642077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.
    Finnema SJ; Halldin C; Bang-Andersen B; Bundgaard C; Farde L
    Psychopharmacology (Berl); 2015 Nov; 232(21-22):4159-67. PubMed ID: 25980484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
    Kim E; Howes OD; Park JW; Kim SN; Shin SA; Kim BH; Turkheimer FE; Lee YS; Kwon JS
    Psychol Med; 2016 Jan; 46(2):357-66. PubMed ID: 26423910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
    Klein N; Sacher J; Geiss-Granadia T; Attarbaschi T; Mossaheb N; Lanzenberger R; Pötzi C; Holik A; Spindelegger C; Asenbaum S; Dudczak R; Tauscher J; Kasper S
    Psychopharmacology (Berl); 2006 Oct; 188(3):263-72. PubMed ID: 16955282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram.
    Warwick JM; Carey PD; Cassimjee N; Lochner C; Hemmings S; Moolman-Smook H; Beetge E; Dupont P; Stein DJ
    Metab Brain Dis; 2012 Jun; 27(2):151-8. PubMed ID: 22350963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo.
    Baldwin DS; Asakura S; Koyama T; Hayano T; Hagino A; Reines E; Larsen K
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):1062-9. PubMed ID: 26971233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.
    Lenze EJ; Goate AM; Nowotny P; Dixon D; Shi P; Bies RR; Lotrich FK; Rollman BL; Shear MK; Thompson PA; Andreescu C; Pollock BG
    J Clin Psychopharmacol; 2010 Dec; 30(6):672-7. PubMed ID: 21105279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neurobiology and pharmacotherapy of social phobia].
    Aouizerate B; Martin-Guehl C; Tignol J
    Encephale; 2004; 30(4):301-13. PubMed ID: 15538306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123 I]β-CIT SPECT study.
    Rominger A; Cumming P; Brendel M; Xiong G; Zach C; Karch S; Tatsch K; Bartenstein P; la Fougère C; Koch W; Pogarell O
    Eur Neuropsychopharmacol; 2015 Jun; 25(6):873-81. PubMed ID: 25819144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
    Carey PD; Warwick J; Niehaus DJ; van der Linden G; van Heerden BB; Harvey BH; Seedat S; Stein DJ
    BMC Psychiatry; 2004 Oct; 4():30. PubMed ID: 15482603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression.
    Smith GS; Kahn A; Sacher J; Rusjan P; van Eimeren T; Flint A; Wilson AA
    Am J Geriatr Psychiatry; 2011 Dec; 19(12):1016-25. PubMed ID: 21841458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.
    Lenze EJ; Rollman BL; Shear MK; Dew MA; Pollock BG; Ciliberti C; Costantino M; Snyder S; Shi P; Spitznagel E; Andreescu C; Butters MA; Reynolds CF
    JAMA; 2009 Jan; 301(3):295-303. PubMed ID: 19155456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
    Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [
    Kim E; Howes OD; Kim BH; Chon MW; Seo S; Turkheimer FE; Lee JS; Lee YS; Kwon JS
    Clin Pharmacokinet; 2017 Apr; 56(4):371-381. PubMed ID: 27557550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.